CRT in patients with heart failure in NYHA I-II class Review article
Article Sidebar
Published:
Dec 31, 2010
Keywords:
cardiac resynchronization therapy, heart failure, guidelines
Main Article Content
Abstract
Heart failure (HF) is one of the most important heart diseases and because of its frequency, unfavorable prognosis and high cost of therapy makes a serious problem in current medicine. The clinical effects of cardiac resynchronization therapy (CRT) have been evaluated in a large number of randomized clinical trials and improves clinical condition and prognosis in HF patients. So far CRT was recommended to reduce mortality and morbidity in patients in NYHA III-IV classes who have a reduced EF ≤ 35% and QRS width ≥ 120ms. Two recent, randomized trials’ MARIT-CRT and REVERSE demonstrated reduced morbidity in mild HF. CRT is actually also recommended to reduce morbidity or to prevent disease progression in patients with HF in NYHA II class who have a reduced EF ≤ 35% and QRS width ≥ 150 ms.
Article Details
How to Cite
Jędrzejczyk-Patej, E., Pruszkowska-Skrzep, P., & Kalarus, Z. (2010). CRT in patients with heart failure in NYHA I-II class. Medycyna Faktow (J EBM), 3(4(9), 32-36. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2562
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Dickstein K., Cohen-Solal A., Filippatos G. et al.: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 2008 Oct; 10 (10): 933-89.
2. Dickstein K., Vardas P.E., Auricchio A. et al.: 2010 Focused update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur. Heart J. 2010 [online: DOI:10.1093/eurheartj/ehq337].
3. Linde C., Abraham W.T., Gold M.R. et al.: Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol. 2008; 52: 1834-1843.
4. Daubert C., Gold M.R., Abraham W.T. et al.: Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol. 2009; 54: 1837-1846.
5. Moss A.J., Hall W.J., Cannom D.S. et al.: Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 2009; 361: 1329-1338.
6. Abraham W.T., Fisher W.G., Smith A.L. et al.: Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 2002; 346: 1845-1853.
7. Young J.B., Abraham W.T., Smith A.L. et al.: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685-2694.
8. Bristow M.R., Saxon L.A., Boehmer J. et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic vheart failure. N. Engl. J. Med. 2004; 350: 2140-2150.
9. Cleland J.G., Daubert J.C., Erdmann E. et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 2005; 352: 1539-1549.
10. Tang A.S., Ellenbogen K.A.: A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. Curr. Opin. Cardiol. 2006; 21: 78-82.
11. Fox M., Mealing S., Anderson R. et al.: The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol. Assess. 2007; 11: iii-iv, ix-248.
12. Woo G.W., Petersen-Stejskal S., Johnson J.W. et al.: Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J. Interv. Card. Electrophysiol. 2005; 12: 107-113.
13. Santaularia-Tomas M., Abraham T.P.: Criteria predicting response to CRT: is more better? Eur. Heart J. 2009; 30: 2835-2837.
14. Byrne M.J., Helm R.H., Daya S. et al.: Diminished left ventricular dyssynchrony and impact of resynchronization in failing hearts with right versus left bundle branch block. J. Am. Coll. Cardiol. 2007; 50: 1484-1490.
15. Adelstein E.C., Saba S.: Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am. J. Cardiol. 2009; 103: 238-242.
16. Wokhlu A., Rea R.F., Asirvatham S.J. et al.: Upgrade and de novo cardiac resynchronization therapy: Impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm 2009; 6: 1439-1447.
2. Dickstein K., Vardas P.E., Auricchio A. et al.: 2010 Focused update of ESC guidelines on device therapy in heart failure. An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur. Heart J. 2010 [online: DOI:10.1093/eurheartj/ehq337].
3. Linde C., Abraham W.T., Gold M.R. et al.: Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J. Am. Coll. Cardiol. 2008; 52: 1834-1843.
4. Daubert C., Gold M.R., Abraham W.T. et al.: Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J. Am. Coll. Cardiol. 2009; 54: 1837-1846.
5. Moss A.J., Hall W.J., Cannom D.S. et al.: Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 2009; 361: 1329-1338.
6. Abraham W.T., Fisher W.G., Smith A.L. et al.: Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 2002; 346: 1845-1853.
7. Young J.B., Abraham W.T., Smith A.L. et al.: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685-2694.
8. Bristow M.R., Saxon L.A., Boehmer J. et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic vheart failure. N. Engl. J. Med. 2004; 350: 2140-2150.
9. Cleland J.G., Daubert J.C., Erdmann E. et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 2005; 352: 1539-1549.
10. Tang A.S., Ellenbogen K.A.: A futuristic perspective on clinical studies of cardiac resynchronization therapy for heart failure patients. Curr. Opin. Cardiol. 2006; 21: 78-82.
11. Fox M., Mealing S., Anderson R. et al.: The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol. Assess. 2007; 11: iii-iv, ix-248.
12. Woo G.W., Petersen-Stejskal S., Johnson J.W. et al.: Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J. Interv. Card. Electrophysiol. 2005; 12: 107-113.
13. Santaularia-Tomas M., Abraham T.P.: Criteria predicting response to CRT: is more better? Eur. Heart J. 2009; 30: 2835-2837.
14. Byrne M.J., Helm R.H., Daya S. et al.: Diminished left ventricular dyssynchrony and impact of resynchronization in failing hearts with right versus left bundle branch block. J. Am. Coll. Cardiol. 2007; 50: 1484-1490.
15. Adelstein E.C., Saba S.: Usefulness of baseline electrocardiographic QRS complex pattern to predict response to cardiac resynchronization. Am. J. Cardiol. 2009; 103: 238-242.
16. Wokhlu A., Rea R.F., Asirvatham S.J. et al.: Upgrade and de novo cardiac resynchronization therapy: Impact of paced or intrinsic QRS morphology on outcomes and survival. Heart Rhythm 2009; 6: 1439-1447.